Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual propertyPiyusha P. Pagare, Martin K. Safo, Abdelsattar M. Omar et al.|Expert Opinion on Therapeutic Patents|2021Cited by 22
Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease miceAndrew N. Fleischman, Osheiza Abdulmalik, David R. Light et al.|Blood|2025Cited by 1
ILX-002 A Direct HbS Polymerization Inhibitor for the Treatment of Sickle Cell DiseaseOsheiza Abdulmalik, Martin K. Safo, Abdelsattar M. Omar et al.|Journal of sickle cell disease.|2024Cited by 0
A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - <i>In Vivo</i> Efficacy of Ilx-002 in Humanized MiceOsheiza Abdulmalik, Andrew N. Fleischman, Kandace Gollomp et al.|Blood|2024Cited by 0